Protagonist Therapeutics, Inc. (PTGX)
Upgrades & Downgrades
Latest PTGX news
Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock?
23 September 2022
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Protagonist: Too Many Red Flags
8 June 2022
Protagonist has recently faced a number of mishaps. These make the stock risky.
3 Biotech Stocks to Buy Before They Boom
1 June 2022
It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations. The post 3 Biotech Stocks to Buy Before They Boom appeared first on Inv...
Protagonist Therapeutics to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera...
26 May 2022
Enrollment completed and dosing resumed in the ongoing Phase 2 REVIVE study Resumption of rusfertide administration after suspension restored therapeutic benefits including hematocrit control, reduced...
A new generation of ulcerative colitis drugs is in development. Will they be the blockbusters that p...
26 May 2022
Pfizer Inc.'s PFE, +0.96% promising ulcerative colitis treatment could generate $1.9 billion in sales by 2030 if it's approved by U.S. regulators next year.
7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years
11 May 2022
Finding micro-cap stocks to buy requires a bit of everything, including patience. Today's plan is to pick from the top of the IWC ETF.
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
4 May 2022
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 35.82% and 33.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stoc...
Why Protagonist Therapeutics Shares Are Crashing Today
26 April 2022
Protagonist Therapeutics Inc (NASDAQ: PTGX) announced topline results from the Phase 2 IDEAL study of PN-943 in moderate-to-severe ulcerative colitis (UC) patients. 159 patients with moderate-to-sever...
Protagonist Therapeutics shares slid after sharing Phase 2 data for its experimental ulcerative coli...
26 April 2022
Shares of Protagonist Therapeutics Inc. PTGX, -0.58% tumbled 30.8% in premarket trading on Tuesday the day after the company said a Phase 2 clinical trial that gave patients a higher dose of its exper...
FDA Intends To Revoke Protagonist Therapeutics' Rusfertide Breakthrough Tag In Rare Form Of Blood Ca...
14 April 2022
Protagonist Therapeutics Inc (NASDAQ: PTGX) received a letter from the FDA indicating the agency's intent to rescind Breakthrough Therapy Designation for the company's rusfertide product candidate in ...